The Journal of Immunology, Vol 142, Issue 12 4233-4240, Copyright © 1989 by American Association of Immunologists

ARTICLES

Increment in the Ta1+ cells in the peripheral blood and thyroid tissue of patients with Graves' disease

K Eguchi, Y Ueki, C Shimomura, T Otsubo, H Nakao, K Migita, A Kawakami, M Matsunaga, H Tezuka and N Ishikawa
First Department of Internal Medicine, Nagasaki University School of Medicine, Japan.

The present study utilized the anti-Ta1 mAb to characterize the cell surface phenotypes of peripheral blood and intrathyroidal lymphocytes in patients with Graves' disease. We found an increase in PBL bearing the Ta1 Ag in untreated patients. The euthyroid patients in remission, induced by antithyroidal drugs, radioisotope therapy, and subtotal thyroidectomy, had lower percentages of Ta1+ cells than did untreated patients. An increased percentage of Ta1+ cells in untreated patients was found in both CD4+ cells and CD8+ cells. The ratio of CD4+Ta1+ cells to CD8+Ta1+ cells in untreated patients was significantly higher than that of normal subjects. There was a positive correlation between the percentage of Ta1+ cells and the level of anti-TSH receptor antibody. In this prospective study, the proportion of Ta1+ cells was decreased in parallel with the reduction in anti-TSH receptor antibody and free T3 levels. In the chronically treated patients, the proportion of Ta1+ cells in the thyroid tissue was, yet similar to that in the peripheral blood, markedly increased in comparison to that of normal subjects. In contrast to Ta1+ cells, the thyroid tissue had a significantly higher percentage of HLA-DR+ T cells than did the paired peripheral blood. The proliferative responses of the Ta1+ cell-enriched population isolated from untreated patients toward thyroglobulin and microsomal Ag were markedly higher than those in a Ta1+ cell-depleted population, but both populations were able to respond equally to PHA. These results suggest that the Ta1+ cells may include Ag-triggered memory cells that are reactive with thyroid-specific Ag. Furthermore, monitoring such cells may provide an objective measure of abnormal immunologic activity.

This article has been cited by other articles:

				K. Ohnuma, M. Uchiyama, T. Yamochi, K. Nishibashi, O. Hosono, N. Takahashi, S. Kina, H. Tanaka, X. Lin, N. H. Dang, et al. Caveolin-1 Triggers T-cell Activation via CD26 in Association with CARMA1 J. Biol. Chem., March 30, 2007; 282(13): 10117 - 10131. [Abstract] [Full Text] [PDF]

				K. Ohnuma, T. Yamochi, M. Uchiyama, K. Nishibashi, S. Iwata, O. Hosono, H. Kawasaki, H. Tanaka, N. H. Dang, and C. Morimoto CD26 Mediates Dissociation of Tollip and IRAK-1 from Caveolin-1 and Induces Upregulation of CD86 on Antigen-Presenting Cells Mol. Cell. Biol., September 1, 2005; 25(17): 7743 - 7757. [Abstract] [Full Text] [PDF]

				E. P. Boonacker, E. A. Wierenga, H. H. Smits, and C. J.F. Van Noorden CD26/DPPIV Signal Transduction Function, but Not Proteolytic Activity, Is Directly Related to Its Expression Level on Human Th1 and Th2 Cell Lines as Detected with Living Cell Cytochemistry J. Histochem. Cytochem., September 1, 2002; 50(9): 1169 - 1177. [Abstract] [Full Text] [PDF]

				L. Ho, U. Aytac, L. C. Stephens, K. Ohnuma, G. B. Mills, K. S. McKee, C. Neumann, R. LaPushin, F. Cabanillas, J. L. Abbruzzese, et al. In Vitro and in Vivo Antitumor Effect of the Anti-CD26 Monoclonal Antibody 1F7 on Human CD30+ Anaplastic Large Cell T-Cell Lymphoma Karpas 299 Clin. Cancer Res., July 1, 2001; 7(7): 2031 - 2040. [Abstract] [Full Text] [PDF]